Download PDF
Arzneimittelforschung 2011; 61(2): 112-119
DOI: 10.1055/s-0031-1296176
Therapeutics for States of Deficiency
Editio Cantor Verlag Aulendorf (Germany)

Physicochemical and toxicological characterization of a new generic iron sucrose preparation

Thomas Meier
1   Cilag AG, Schaffhausen, Switzerland
,
Patricia Schropp
2   Bioservice Scientific Laboratories GmbH, Planegg, Germany
,
Christian Pater
1   Cilag AG, Schaffhausen, Switzerland
,
Anne-Laure Leoni
2   Bioservice Scientific Laboratories GmbH, Planegg, Germany
,
Van Van Khov-Tran
3   Azad Pharma AG, Toffen, Switzerland
,
Peter Elford
3   Azad Pharma AG, Toffen, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2011 (online)

    Permissions and Reprints

Abstract

Intravenous iron preparations are key components in the management of anaemia of various etiologies. These iron-carbohydrate complexes permit safe systemic delivery of iron, whilst protecting from the potential toxic effects of over-saturation. This in turn permits efficient haematopoiesis following erythropoietin administration. Since the rate of release of iron is dependent upon the structure of this iron-carbohydrate complex, it is essential to ensure that an intravenous iron preparation is well characterized and its properties documented. This report describes physicochemical and toxicological studies into a new iron sucrose generic preparation, “Iron Sucrose Azad (ISA)”, using the original iron sucrose product as reference. It could be demonstrated that the specifications and physicochemical characteristics of ISA reflect those of the reference product. Furthermore, in a rat model previously shown to identify possible toxicological effects of “unsimilar” iron sucrose preparations, ISA was found to have the same properties as the reference product, with both being well tolerated.

Key words

Iron Sucrose Azad - Iron sucrose, generic - Pysicochemical characterization - Toxicity
 

  • References

  • 1 Hsu C, McCulloch CE, Curhan GC. Iron status and haemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002; 13: 2783-6
    CrossrefPubMedGoogle Scholar
  • 2 Panesar A, Agarwal R. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. AmJ Kidney Dis. 2002; 40: 924-31
    PubMedGoogle Scholar
  • 3 Fishbane S. Safety in iron management. Am J Kidney Dis. 2003; 41: S18-26
    PubMedGoogle Scholar
  • 4 Danielson BG. Structure, chemistry and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004; 15: S93-8
    PubMedGoogle Scholar
  • 5 Agarwal R. Transferrin saturation with intravenous irons: An in vitro study. Kidney Int. 2004; 66: 1139-44
    CrossrefPubMedGoogle Scholar
  • 6 Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ et al Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106: 2212-7
    CrossrefPubMedGoogle Scholar
  • 7 Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol. 2006; 1: S24-31
    CrossrefPubMedGoogle Scholar
  • 8 Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Drug Res. 1992; 42: 1439-52
    PubMedGoogle Scholar
  • 9 Van Wyck DB, Danielson BG, Arnoff GR. Making sense: A scientific approach to intravenous iron therapy. J Am Soc Nephrol. 2004; 15: S91-2
    CrossrefPubMedGoogle Scholar
  • 10 Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S et al Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000; 11: 530-8
    PubMedGoogle Scholar
  • 11 Schiesser D, Binet I, Tsinalis D, Dickenmann M, Keusch G, Schmidli M et al Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Neprol Dial Transplant. 2006; 21: 2841-5
    CrossrefPubMedGoogle Scholar
  • 12 Toblli J, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung. 2009; 59: 176-90
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Toblli J, Cao G, Oliveri L, Angerosa M. Differences between the original intravenous iron sucrose complex Venofer® and the iron sucrose similar Generis® and potential implications. Port J Nephrol Hypert. 2009; 23: 53-63
    PubMedGoogle Scholar
  • 14 Kudasheva D, Lai J, Ulman A, Cowman MK. Structure of nanoparticles in parenteral formulations. J Inorg Biochem. 2004; 98: 1757-69
    CrossrefPubMedGoogle Scholar
  • 15 Erni I, Oswald N, Rich HW, Schneider W. Chemical characterization of iron (III)-hydroxide-dextrin complexes. Arzneimittelforschung. 1984; 34: 1555-9
    PubMedGoogle Scholar
  • 16 OECD Environmental Health and Safety Publications: Principles of Good Laboratory Practice and Compliance Monitoring, No.1. Environment Directorate, Organisation for Economic Co-operation and Development. OECD: Paris; 1998
    PubMed
  • 17 Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem. 2004; 98: 1757-69
    CrossrefPubMedGoogle Scholar
  • 18 Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM. “Oversaturation” of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant. 1996; 11: 820-42
    CrossrefPubMedGoogle Scholar
  • 19 Food and Drug Administration–Center for Drug Evaluation and Research. Application Number: 21-135. Pharmacology Review of NDA for Venofer®. August 6th 2000.
    PubMed
  • 20 Legssyer R, Geisser P, McArdle H, Crichton RR, Ward RJ. Comparison of injectable iron complexes in their ability to iron load tissues and induce oxidative stress. Biometals. 2003; 16: 425-33
    CrossrefPubMedGoogle Scholar
  • 21 Summary of Product Characteristics (SPC) for Venofer 20 mg/ml Solution for Injection [Internet]. Electronic Medicines Compedium. Datapharma, London; 2006. [Cited: 2010 Dec 8] Available from: http://www.medicines.org.uk/EMC/medicine/14438/SPC/Venofer+20+mg+ml+Solution+for+Injection
    PubMed
  • 22 Chandler G, Harchowal J, Macdougall I. C. Intravenous iron sucrose: establishing a safe dose. Am Kidney Dis. 2001; 38: 988-91
    PubMedGoogle Scholar
  • 23 Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC et al Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest. 2002; 32: 36-41
    CrossrefPubMedGoogle Scholar
  • 24 Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000; 15: 1827-34
    CrossrefPubMedGoogle Scholar
  • 25 Espósito BP, Breuer A, Stotkli I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2000; 32: 42-9
    PubMedGoogle Scholar
  • 26 Nyovad O, Danielsen H, Madsen S. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet. 1994; 344: 1305-6
    PubMedGoogle Scholar
  • 27 Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. AmJ Kidney Dis. 1999; 34: S40-6
    PubMedGoogle Scholar